An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

Inclusion Criteria: * Signed and dated IRB/EC-approved informed consent * Age 18 years or older * Histologically confirmed prostate adenocarcinoma * Metastatic HRPC * Received prior castration by orchidectomy and/or LH-RH agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other hormonal agents. * Tumor disease must be progressive after a first line using docetaxel based chemotherapy, eventually in association with estramustine. Docetaxel based regimen may have been interrupted and restarted. Patient must have either measurable (RECIST criteria) or non-measurable (bone) disease and/or clinical progression (bone pain) and/or biological progression (PSA Working Group criteria). * Discontinuation from previous chemotherapy and/or radiation therapy at least 4 weeks prior to treatment initiation * Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale * Patient of child bearing potential must use effective contraception. Female partners of treated patients with child bearing potential must use oral contraceptives or intra uterine device (IUD) * Life expectancy of at least 3 months * Resolution of all acute toxic effects of any prior local treatment to NCI CTCAE grade 1 * Patients must have adequate organ functions defined * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * Patient covered by the National Health System Exclusion Criteria: * Prior treatment with sunitinib or other antiangiogenic agent * More than 1 line of chemotherapy * External beam radiotherapy for ≥ 50% of bone marrow * Uncontrolled hypertension (systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg despite optimal medical management) * Any of the following within 12 months prior to treatment initiation: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, thrombotic or embolic events such as cerebrovascular accident including transient ischemic attack * Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade * Treatment with anticonvulsant agents and treatment with therapeutic doses of coumarin-derivative anticoagulants such as warfarin currently or within 2 weeks prior to first day of Sunitinib administration. Low dose of warfarin for deep vein thrombosis prophylaxis is permitted (up to 2 mg/day) and low molecular weight heparin is allowed * Any medical condition that might interfere with oral medication absorption * Known or suspected brain metastasis, or carcinomatous meningitis, or spinal cord compression * Diagnosis of any second malignancy within the last 3 years, with the exception of treated basal cell or squamous cell carcinoma and pT1/a bladder cancer with no evidence of recurrent disease for 12 months * Any acute or chronic medical or psychiatric disorder incompatible with the study * Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness * Treatment with others investigational drugs or participation in another clinical trial within the past 4 weeks, or concomitantly with this trial